On January 4, 2021 Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, reported that Joseph Oliveto, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright BIOCONNECT Virtual Conference being held on January 10-13, 2022 (Press release, Milestone Pharmaceuticals, JAN 4, 2022, View Source [SID1234598152]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The prerecorded fireside chat will become available on Monday, January 10, 2022 at 7:00am ET and can be accessed in the News & Events section of Milestone’s website at www.milestonepharma.com. An archived replay of the fireside chat will be available on the same website 90 days following the presentation.

On January 4, 2021 Perrigo Company plc (NYSE; TASE: PRGO), reported that President and CEO, Murray S. Kessler is scheduled to present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 3:45 PM (EST) (Press release, Perrigo Company, JAN 4, 2022, View Source [SID1234598151]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Interested parties can access the presentation webcast on the Perrigo website at View Source

On January 4, 2022 Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, reported that Marc N. Casper, chairman, president and chief executive officer, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 8:15 a.m. (EST) (Press release, Thermo Fisher Scientific, JAN 4, 2022, View Source [SID1234598150]). Among other topics, Mr. Casper will provide the company’s current perspective on its business and expectations for future financial performance.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

You can access the webcast of the presentation via the Investors section of our website, www.thermofisher.com.

On January 4, 2022 iSpecimen Inc. (Nasdaq: ISPC) ("iSpecimen" or the "Company"), an online marketplace for human biospecimens, reported that Christopher Ianelli, MD, PhD, CEO and President of iSpecimen, will participate in the H.C. Wainwright BioConnect Conference to be held virtually on January 10-13, 2022 (Press release, iSpecimen, JAN 4, 2022, https://www.prnewswire.com/news-releases/ispecimen-to-participate-in-the-hc-wainwright-bioconnect-conference-on-january-10-13-2022-301453120.html [SID1234598149]). Dr. Ianelli’s corporate presentation will be available on-demand starting Monday, January 10th at 7:00 a.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

For more information about the H.C. Wainwright BioConnect Conference, or to schedule a one-on-one meeting with iSpecimen’s management, please contact your H.C. Wainwright representative directly or KCSA Strategic Communications at [email protected].

On January 4, 2022 Johnson & Johnson (NYSE: JNJ) reported that its Board of Directors has declared a cash dividend for the first quarter of 2022 of $1.06 per share on the company’s common stock (Press release, Johnson & Johnson, JAN 4, 2022, View Source;johnson-announces-quarterly-dividend-for-first-quarter-2022-301452880.html [SID1234598147]). The dividend is payable on March 8, 2022 to shareholders of record at the close of business on February 22, 2022. The ex-dividend date is February 18, 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!